AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33284796 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon supplementation
Number of subjects: 375
Study 33284796 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 375
Study 34863673 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-Assisted Peer Feedback (VAPF)
Number of subjects: 251
Study 34863673 — intervention group
Group type: COMPARATOR
Intervention: Qualified Instructor Feedback (QIF)
Number of subjects: 251
Study 32238086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower seat height (5.08 cm below lower-leg length)
Number of subjects: 50
Study 32238086 — intervention group
Group type: COMPARATOR
Intervention: Higher seat heights
Number of subjects: 50
Study 32238086 — intervention group
Group type: EXPERIMENTAL
Intervention: All seat heights tested
Number of subjects: 50
Study 32352877 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education (GPR)
Number of subjects: 39
Study 32352877 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises (SG)
Number of subjects: 39
Study 35930291 — intervention group
Group type: EXPERIMENTAL
Intervention: Erect sitting posture
Number of subjects: 0
Study 35930291 — intervention group
Group type: COMPARATOR
Intervention: Slouched sitting posture
Number of subjects: 0
Study 33038227 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma (CP)
Number of subjects: 241
Study 33038227 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 241
Study 32362349 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban
Number of subjects: 0
Study 32362349 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 32362349 — intervention group
Group type: COMPARATOR
Intervention: Standard enoxaparin prophylaxis
Number of subjects: 0
Study 32362349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35066950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame Oil (SO)
Number of subjects: 77
Study 35066950 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola Oil (CO)
Number of subjects: 77
Study 35066950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame-Canola Oil (SCO)
Number of subjects: 77
Study 33158717 — intervention group
Group type: EXPERIMENTAL
Intervention: Shufeng Jiedu capsules (SFJDC) added to standard antiviral therapy (AVD)
Number of subjects: 0
Study 33158717 — intervention group
Group type: COMPARATOR
Intervention: Shufeng Jiedu capsules (SFJDC)
Number of subjects: 0
Study 33161148 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise facilitator intervention (EFI)
Number of subjects: 449
Study 33161148 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 449
Study 32238262 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic-impregnated shunt
Number of subjects: 1605
Study 32238262 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard shunt
Number of subjects: 1605
Study 32238262 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated shunt
Number of subjects: 1605
Study 35189953 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day for 10 weeks
Number of subjects: 84
Study 32924674 — intervention group
Group type: COMPARATOR
Intervention: current HPD fit-training method
Number of subjects: 341
Study 32924674 — intervention group
Group type: EXPERIMENTAL
Intervention: experiential HPD (eHPD) fit-training method
Number of subjects: 341
Study 32924674 — intervention group
Group type: EXPERIMENTAL
Intervention: integrated fit-training method
Number of subjects: 341
Study 32167131 — intervention group
Group type: EXPERIMENTAL
Intervention: Borage oil (BO) supplementation (37% LA and 23% GLA) for 4 weeks
Number of subjects: 64
Study 32167131 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (SO) supplementation (50% LA and 0% GLA) for 4 weeks
Number of subjects: 64
Study 32167131 — intervention group
Group type: EXPERIMENTAL
Intervention: Borage oil (BO) supplementation
Number of subjects: 64
Study 33764243 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaheuristic algorithms (ant colony optimization, simulated annealing, genetic algorithm, large neighborhood search, greedy randomized adaptive search procedures)
Number of subjects: 0
Study 33764243 — intervention group
Group type: EXPERIMENTAL
Intervention: GIS approaches
Number of subjects: 0
Study 34126269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 346
Study 34126269 — intervention group
Group type: COMPARATOR
Intervention: Contact force–guided radiofrequency ablation
Number of subjects: 346
Study 34126269 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAT presence
Number of subjects: 346
Study 34126269 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAT timing
Number of subjects: 346
Study 34126269 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAT burden
Number of subjects: 346
Study 32718816 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVΔG vaccine (6.5 log10 CCID50)
Number of subjects: 48
Study 32718816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 35321334 — intervention group
Group type: EXPERIMENTAL
Intervention: Down-regulation ovulation-induction (DROI)
Number of subjects: 330
Study 35321334 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement treatment (HRT)
Number of subjects: 330
Study 32753547 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line pembrolizumab
Number of subjects: 234
Study 36495282 — intervention group
Group type: EXPERIMENTAL
Intervention: pFMI (90-µg)
Number of subjects: 0
Study 36495282 — intervention group
Group type: COMPARATOR
Intervention: CSF
Number of subjects: 0
Study 36495282 — intervention group
Group type: EXPERIMENTAL
Intervention: pFMI (fasted)
Number of subjects: 0
Study 36495282 — intervention group
Group type: EXPERIMENTAL
Intervention: pFMI (fed)
Number of subjects: 0
Study 36495282 — intervention group
Group type: COMPARATOR
Intervention: CSF (fasted)
Number of subjects: 0
Study 34455726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lettuce seed syrup (5 mL twice daily)
Number of subjects: 50
Study 34455726 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup (5 mL twice daily)
Number of subjects: 50
Study 32910478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab administered after CRT (arm 1)
Number of subjects: 52
Study 32910478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab administered during CRT (arm 2)
Number of subjects: 52
Study 32910478 — intervention group
Group type: COMPARATOR
Intervention: Both arms (arm 1 and arm 2)
Number of subjects: 52
Study 35368220 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 96
Study 35368220 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 96
Study 34329541 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate urinary catheter removal
Number of subjects: 2
Study 34329541 — intervention group
Group type: COMPARATOR
Intervention: Prolonged indwelling catheterization (control)
Number of subjects: 2
Study 34476445 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved atraumatic restorative treatment (ART) with high-intensity glass ionomer cement
Number of subjects: 262
Study 34476445 — intervention group
Group type: COMPARATOR
Intervention: Conventional cavity preparation and composite resin filling (Control)
Number of subjects: 262
Study 35863061 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month DAPT
Number of subjects: 488
Study 35863061 — intervention group
Group type: COMPARATOR
Intervention: 6-month DAPT
Number of subjects: 488
Study 34639778 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 s phenol application
Number of subjects: 27
Study 34639778 — intervention group
Group type: COMPARATOR
Intervention: 60 s phenol application
Number of subjects: 27
Study 32895339 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi Interventional Package (MIP) including reflexology foot massage, dietary modification, moderate intensity exercise, and structured education for 12 weeks
Number of subjects: 60
Study 32895339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Interventions (LI) including dietary modification, moderate intensity exercise, and structured education for 12 weeks
Number of subjects: 60
Study 32895339 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving routine care
Number of subjects: 60
Study 34767321 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin G benzathine injections every 4 weeks for 2 years
Number of subjects: 916
Study 34767321 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 916
Study 33935089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over the right DLPFC
Number of subjects: 40
Study 33935089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over the left DLPFC
Number of subjects: 40
Study 33935089 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tDCS)
Number of subjects: 40
Study 32429865 — intervention group
Group type: EXPERIMENTAL
Intervention: Household size
Number of subjects: 30960
Study 32429865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex (female)
Number of subjects: 30960
Study 32429865 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with both parents
Number of subjects: 30960
Study 32429865 — intervention group
Group type: EXPERIMENTAL
Intervention: Income quartile (2nd)
Number of subjects: 30960
Study 32429865 — intervention group
Group type: EXPERIMENTAL
Intervention: Income quartile (4th)
Number of subjects: 30960
Study 32429865 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (5 to 9 years)
Number of subjects: 30960
Study 32429865 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (15 to 18 years)
Number of subjects: 30960
Study 32429865 — intervention group
Group type: EXPERIMENTAL
Intervention: Residency in a non-owned or non-tenancy house
Number of subjects: 30960
Study 33930353 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG-Ring group
Number of subjects: 102
Study 33930353 — intervention group
Group type: COMPARATOR
Intervention: CABG-alone group
Number of subjects: 102
Study 36482520 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of glucosyl hesperidin per day
Number of subjects: 0
Study 36482520 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of glucosyl hesperidin per day
Number of subjects: 0
Study 36482520 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosyl hesperidin
Number of subjects: 0
Study 32460904 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress induction
Number of subjects: 85
Study 32460904 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 85
Study 32719880 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype EHR application
Number of subjects: 13
Study 32719880 — intervention group
Group type: COMPARATOR
Intervention: Regular EHR
Number of subjects: 13
Study 36375587 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic capture without anterior vitrectomy (group 1)
Number of subjects: 37
Study 36375587 — intervention group
Group type: COMPARATOR
Intervention: In-the-bag IOL with anterior vitrectomy (group 2)
Number of subjects: 37
Study 32970236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 185
Study 32970236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 32077470 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP(3‐30)NH2+exendin(9‐39)NH2
Number of subjects: 12
Study 32077470 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP(3‐30)NH2
Number of subjects: 12
Study 32077470 — intervention group
Group type: EXPERIMENTAL
Intervention: exendin(9‐39)NH2
Number of subjects: 12
Study 32077470 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 33431616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1.5%
Number of subjects: 30
Study 33431616 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study 36143083 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) intervention, 12 weeks, 3 sessions per week, 18 min per session (3 sets of 8 bouts of 15 s run at 100% MAS, separated by 8 bouts of 15 s recovery run at 50% MAS)
Number of subjects: 40
Study 36143083 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) intervention
Number of subjects: 40
Study 36143083 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal behaviors)
Number of subjects: 40
Study 33645906 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 12
Study 32739495 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Anakinra (100 mg daily for 14 days), Pentoxifylline (400 mg three times a day for 28 days), and Zinc sulfate (220 mg orally once daily for 6 months)
Number of subjects: 104
Study 32739495 — intervention group
Group type: COMPARATOR
Intervention: Standard of care therapy including Methylprednisolone (32 mg orally once daily for 28 days)
Number of subjects: 104
Study 35143513 — intervention group
Group type: COMPARATOR
Intervention: Arm 2: access to ARMADILLO SMS information pushed to their phone
Number of subjects: 712
Study 35143513 — intervention group
Group type: COMPARATOR
Intervention: Arm 1: access to ARMADILLO’s SMS information on-demand
Number of subjects: 712
Study 35143513 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (no SMS)
Number of subjects: 712
Study 34045241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Glycemic Index (GI)
Number of subjects: 1279
Study 34045241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Glycemic Load (GL)
Number of subjects: 1279
Study 34045241 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber
Number of subjects: 1279
Study 32365232 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment rules (ITRs) using information from electronic health records (EHRs)
Number of subjects: 0
Study 32365232 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-learning and modified matched-learning algorithm for estimation
Number of subjects: 0
Study 35133630 — intervention group
Group type: EXPERIMENTAL
Intervention: SleepLife® intervention (education on using the SleepLife® application and access to the SleepLife® portal)
Number of subjects: 75
Study 35133630 — intervention group
Group type: EXPERIMENTAL
Intervention: SleepLife® intervention
Number of subjects: 75
Study 35133630 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no education on using the SleepLife® application)
Number of subjects: 75
Study 33221914 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP of 40-50 mmHg during CPB
Number of subjects: 193
Study 33221914 — intervention group
Group type: COMPARATOR
Intervention: MAP of 70-80 mmHg during CPB
Number of subjects: 193
Study 32045662 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in AIRWAYS-2 trial
Number of subjects: 1523
Study 32045662 — intervention group
Group type: EXPERIMENTAL
Intervention: Study training and support
Number of subjects: 1523
Study 32045662 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised method of airway management
Number of subjects: 1523
Study 32045662 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise approach to airway management
Number of subjects: 1523
Study 35432984 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine add on treatment (1 mg daily for 7 days, then 0.5 mg daily for another 7 days)
Number of subjects: 160
Study 35432984 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 160
Study 35432984 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine add on treatment
Number of subjects: 160
Study 32591933 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (intervention) received reminders for physical activity adherence.
Number of subjects: 0
Study 32591933 — intervention group
Group type: COMPARATOR
Intervention: Group B (control) did not receive reminders.
Number of subjects: 0
Study 32591933 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (intervention) for muscle strengthening activity.
Number of subjects: 0
Study 32591933 — intervention group
Group type: COMPARATOR
Intervention: Group B (control) for muscle strengthening activity.
Number of subjects: 0
Study 35272871 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise program and health education program
Number of subjects: 0
Study 35272871 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36113902 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery rescripting of an aversive memory
Number of subjects: 52
Study 36113902 — intervention group
Group type: COMPARATOR
Intervention: Progressive relaxation (control condition)
Number of subjects: 52
Study 36113902 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery rescripting
Number of subjects: 52
Study 34374687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 114
Study 34374687 — intervention group
Group type: COMPARATOR
Intervention: CEE + MPA
Number of subjects: 114
Study 34374687 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 114
Study 35461618 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement with device group (InSpace balloon)
Number of subjects: 117
Study 35461618 — intervention group
Group type: COMPARATOR
Intervention: Debridement only group
Number of subjects: 117
Study 34246301 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D [25(OH)D] concentration
Number of subjects: 0
Study 35412076 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education program for 3 months
Number of subjects: 60
Study 34471446 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation near the cervical sympathetic ganglion at 2 Hz
Number of subjects: 20
Study 35139330 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (within 3 days)
Number of subjects: 0
Study 35139330 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery
Number of subjects: 0
Study 32816626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of olive fruit extract (7.5 mg HT) and almond skin extracts (210 mg ASPs)
Number of subjects: 0
Study 32816626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 0
Study 32356027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal probiotic gel with L. plantarum YUN‐V2.0, L. pentosus YUN‐V1.0 and L. rhamnosus YUN‐S1.0 for 10 consecutive days
Number of subjects: 20
Study 32356027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal probiotic gel
Number of subjects: 20
Study 32356027 — intervention group
Group type: EXPERIMENTAL
Intervention: Women needing rescue treatment
Number of subjects: 20
Study 32356027 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical composite score
Number of subjects: 20
Study 35306584 — intervention group
Group type: COMPARATOR
Intervention: Regular PPE
Number of subjects: 10
Study 35306584 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID‐19 PPE
Number of subjects: 10
Study 36403132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutimlimab
Number of subjects: 0
Study 36403132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34218922 — intervention group
Group type: COMPARATOR
Intervention: Mixed tocopherols (TMIX) at 0, 5, 10, or 15 mg/kg of BW daily
Number of subjects: 48
Study 34218922 — intervention group
Group type: COMPARATOR
Intervention: Mixed tocopherols (TMIX)
Number of subjects: 48
Study 34546807 — intervention group
Group type: EXPERIMENTAL
Intervention: RD-PAD (SmartDrive system)
Number of subjects: 22
Study 36308112 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal incisions
Number of subjects: 200
Study 36308112 — intervention group
Group type: EXPERIMENTAL
Intervention: Chevron incisions
Number of subjects: 200
Study 36308112 — intervention group
Group type: EXPERIMENTAL
Intervention: Frown incisions
Number of subjects: 200
Study 36308112 — intervention group
Group type: COMPARATOR
Intervention: Superior incisions
Number of subjects: 200
Study 36308112 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative keratometry
Number of subjects: 200
Study 36308112 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity (UCVA)
Number of subjects: 200
Study 33752449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin
Number of subjects: 2848
Study 33752449 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone
Number of subjects: 2848
Study 33752449 — intervention group
Group type: EXPERIMENTAL
Intervention: Free testosterone
Number of subjects: 2848
Study 32043709 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with everolimus-eluting stents (n=948)
Number of subjects: 1804
Study 32043709 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) (n=957)
Number of subjects: 1804
Study 32043709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCI and CABG
Number of subjects: 1804
Study 35187840 — intervention group
Group type: COMPARATOR
Intervention: Subthreshold Stochastic Resonance Stimulation (SBT-SRS)
Number of subjects: 16
Study 35187840 — intervention group
Group type: COMPARATOR
Intervention: Above-threshold Stochastic Resonance Stimulation (AT-SRS)
Number of subjects: 16
Study 35187840 — intervention group
Group type: COMPARATOR
Intervention: Sham (devices powered off)
Number of subjects: 16
Study 34135190 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one discordant morbidity
Number of subjects: 402
Study 34135190 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one concordant morbidity
Number of subjects: 402
Study 34135190 — intervention group
Group type: EXPERIMENTAL
Intervention: Any comorbidity
Number of subjects: 402
Study 34135190 — intervention group
Group type: COMPARATOR
Intervention: No comorbidity
Number of subjects: 402
Study 32527195 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST) for 4 to 8 weeks
Number of subjects: 10
Study 32527195 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST)
Number of subjects: 10
Study 36354032 — intervention group
Group type: COMPARATOR
Intervention: Single dose mRNA-1273 (100 μg)
Number of subjects: 230
Study 36354032 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose mRNA-1273 (2×100 μg)
Number of subjects: 230
Study 36354032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2-S vaccination
Number of subjects: 230